← All trials
NCT04509973
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 27, 2020
- Primary completion
- Sep 17, 2021
- Completion date
- Feb 17, 2022
- First posted
- Aug 12, 2020
- Last posted
- Sep 1, 2020
- Enrollment
- 1000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Scandinavian Critical Care Trials GroupLead sponsor
- Aarhus UniversityCollaborator
- University of New South WalesCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- Aalborg UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.